nach oben

Erschienen in:

09.07.2023 | Review

Diagnosis and management of Becker muscular dystrophy: the French guidelines

verfasst von: Armelle Magot, Karim Wahbi, France Leturcq, Sandrine Jaffre, Yann Péréon, Guilhem Sole, The French BMD working group

Erschienen in: Journal of Neurology | Ausgabe 10/2023

Einloggen, um Zugang zu erhalten

Abstract

Becker muscular dystrophy (BMD) is one of the most frequent among neuromuscular diseases, affecting approximately 1 in 18,000 male births. It is linked to a genetic mutation on the X chromosome. In contrast to Duchenne muscular dystrophy, for which improved care and management have changed the prognosis and life expectancy of patients, few guidelines have been published for management of BMD. Many clinicians are inexperienced in managing the complications of this disease. In France, a committee of experts from a wide range of disciplines met in 2019 to establish recommendations, with the goal of improving care of patients with BMD. Here, we present the tools to provide diagnosis of BMD as quickly as possible and for differential diagnoses. Then, we describe the multidisciplinary approach essential for optimum management of BMD. We give recommendations for the initial assessment and follow-up of the neurological, respiratory, cardiac, and orthopedic consequences of males who present with BMD. Finally, we describe the optimal therapeutic management of these complications. We also provide guidance on cardiac management for female carriers.

Becker PE, Kiener F (1955) A new X-chromosomal muscular dystrophy. Arch Psychiatr Nervenkr Z Gesamte Neurol Psychiatr 193:427–448PubMedCrossRef

Bushby KM, Thambyayah M, Gardner-Medwin D (1991) Prevalence and incidence of Becker muscular dystrophy. Lancet 337:1022–1024PubMedCrossRef

Koenig M, Hoffman EP, Bertelson CJ et al (1987) Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals. Cell 50:509–517PubMedCrossRef

Hoffman EP, Brown RH, Kunkel LM (1987) Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 51:919–928PubMedCrossRef

Yazaki M, Yoshida K, Nakamura A et al (1999) Clinical characteristics of aged Becker muscular dystrophy patients with onset after 30 years. Eur Neurol 42:145–149PubMedCrossRef

Doriguzzi C, Palmucci L, Mongini T et al (1993) Exercise intolerance and recurrent myoglobinuria as the only expression of Xp21 Becker type muscular dystrophy. J Neurol 240:269–271PubMedCrossRef

Viggiano E, Picillo E, Ergoli M, Cirillo A, Del Gaudio S, Politano L (2017) Skewed X-chromosome inactivation plays a crucial role in the onset of symptoms in carriers of Becker muscular dystrophy. J Gene Med 19(4):e2952CrossRef

Yoshioka M, Yorifuji T, Mituyoshi I (1998) Skewed X inactivation in manifesting carriers of Duchenne muscular dystrophy. Clin Genet 53:102–107PubMedCrossRef

Hoogerwaard EM, Bakker E, Ippel PF et al (1999) Signs and symptoms of Duchenne muscular dystrophy and Becker muscular dystrophy among carriers in The Netherlands: a cohort study. Lancet 353:2116–2119PubMedCrossRef

10.

Mercier S, Toutain A, Toussaint A et al (2013) Genetic and clinical specificity of 26 symptomatic carriers for dystrophinopathies at pediatric age. Eur J Hum Genet 21:855–863PubMedPubMedCentralCrossRef

11.

Birnkrant DJ, Bushby K, Bann CM, Apkon SD, Blackwell A, Brumbaugh D, Case LE, Clemens PR, Hadjiyannakis S, Pandya S, Street N, Tomezsko J, Wagner KR, Ward LM, Weber DR, DMD Care Considerations Working Group (2018) Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. Lancet Neurol 17(3):251–267PubMedPubMedCentralCrossRef

12.

Birnkrant DJ, Bushby K, Bann CM, Alman BA, Apkon SD, Blackwell A, Case LE, Cripe L, Hadjiyannakis S, Olson AK, Sheehan DW, Bolen J, Weber DR, Ward LM, DMD Care Considerations Working Group (2018) Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management. Lancet Neurol 17(4):347–361PubMedPubMedCentralCrossRef

13.

Birnkrant DJ, Bushby K, Bann CM, Apkon SD, Blackwell A, Colvin MK, Cripe L, Herron AR, Kennedy A, Kinnett K, Naprawa J, Noritz G, Poysky J, Street N, Trout CJ, Weber DR, Ward LM, DMD Care Considerations Working Group (2018) Diagnosis and management of Duchenne muscular dystrophy, part 3: primary care, emergency management, psychosocial care, and transitions of care across the lifespan. Lancet Neurol 17(5):445–455PubMedPubMedCentralCrossRef

14.

Méthode d’élaboration d’un protocole national de diagnostic et de soins pour les maladies rares. French Health authority. https://www.has-sante.fr/upload/docs/application/pdf/2012-12/guide_methodologique_pnds.pdf. Accessed Oct 2012.

15.

Taglia A, Petillo R, D’Ambrosio P, Picillo E, Torella A, Orsini C, Ergoli M, Scutifero M, Passamano L, Palladino A, Nigro G, Politano L (2015) Clinical features of patients with dystrophinopathy sharing the 45–55 exon deletion of DMD gene. Acta Myol 34(1):9–13PubMedPubMedCentral

16.

Hermans MCE, Pinto YM, Merkies ISJ et al (2010) Hereditary muscular dystrophies and the heart. Neuromuscul Disord 20:479–492PubMedCrossRef

17.

Melacini P, Fanin M, Danieli GA et al (1996) Myocardial involvement is very frequent among patients affected with subclinical Becker’s muscular dystrophy. Circulation 94:3168–3175PubMedCrossRef

18.

Mavrogeni S, Markousis-Mavrogenis G, Papavasiliou A et al (2015) Cardiac involvement in Duchenne and Becker muscular dystrophy. World J Cardiol 7:410–414PubMedPubMedCentralCrossRef

19.

Ferlini A, Sewry C, Melis MA et al (1999) X-linked dilated cardiomyopathy and the dystrophin gene. Neuromuscul Disord 9:339–346PubMedCrossRef

20.

Mori-Yoshimura M, Mizuno Y, Yoshida S, Ishihara N, Minami N, Morimoto E, Maruo K, Nonaka I, Komaki H, Nishino I, Sekiguchi M, Sato N, Takeda S, Takahashi Y (2019) Psychiatric and neurodevelopmental aspects of Becker muscular dystrophy. Neuromuscul Disord 29(12):930–939PubMedCrossRef

21.

Young HK, Barton BA, Waisbren S, Portales Dale L, Ryan MM, Webster RI, North KN (2008) Cognitive and psychological profile of males with Becker muscular dystrophy. J Child Neurol 23(2):155–162PubMedCrossRef

22.

Hinton VJ, Nereo NE, Fee RJ, Cyrulnik SE (2006) Social behavior problems in boys with Duchenne muscular dystrophy. J Dev Behav Pediatr 27(6):470–476PubMedPubMedCentralCrossRef

23.

Cyrulnik SE, Fee RJ, Batchelder A, Kiefel J, Goldstein E, Hinton VJ (2008) Cognitive and adaptive deficits in young children with Duchenne muscular dystrophy (DMD). J Int Neuropsychol Soc 14(5):853–861PubMedCrossRef

24.

Steele M, Taylor E, Young C, McGrath P, Lyttle BD, Davidson B (2008) Mental health of children and adolescents with Duchenne muscular dystrophy. Dev Med Child Neurol 50(8):638–639PubMedCrossRef

25.

Pascual-Morena C, Cavero-Redondo I, Álvarez-Bueno C, Jiménez-López E, Saz-Lara A, Martínez-García I, Martínez-Vizcaíno V (2023) Global prevalence of intellectual developmental disorder in dystrophinopathies: a systematic review and meta-analysis. Dev Med Child Neurol 65(6):734–744PubMedCrossRef

26.

Pascual-Morena C, Cavero-Redondo I, Reina-Gutiérrez S, Saz-Lara A, López-Gil JF, Martínez-Vizcaíno V (2022) Prevalence of neuropsychiatric disorders in Duchenne and Becker muscular dystrophies: a systematic review and meta-analysis. Arch Phys Med Rehabil 103(12):2444–2453PubMedCrossRef

27.

Pascual-Morena C, Martínez-Vizcaíno V, Saz-Lara A, López-Gil JF, Fernández-Bravo-Rodrigo J, Cavero-Redondo I (2022) Epileptic disorders in Becker and Duchenne muscular dystrophies: a systematic review and meta-analysis. J Neurol 269(7):3461–3469PubMedCrossRef

28.

Daoud F, Angeard N, Demerre B et al (2009) Analysis of Dp71 contribution in the severity of mental retardation through comparison of Duchenne and Becker patients differing by mutation consequences on Dp71 expression. Hum Mol Genet 18:3779–3794PubMedCrossRef

29.

Wang L, Chen M, He R, Sun Y, Yang J, Xiao L, Cao J, Zhang H, Zhang C (2017) Serum creatinine distinguishes Duchenne muscular dystrophy from Becker muscular dystrophy in patients aged ≤ 3 years: a retrospective study. Front Neurol 8(8):196PubMedPubMedCentralCrossRef

30.

Lim AK (2020) Abnormal liver function tests associated with severe rhabdomyolysis. World J Gastroenterol 26(10):1020–1028PubMedPubMedCentralCrossRef

31.

Beltran Papsdorf T, Howard JF, Chahin N (2015) Late-onset Becker muscular dystrophy: refining the clinical features and electrophysiological findings. Muscle Nerve 15:1–3

32.

Tasca G, Iannaccone E, Monforte M et al (2012) Muscle MRI in Becker muscular dystrophy. Neuromuscul Disord 22:100–106CrossRef

33.

Uro-Soste E, Fernandez C, Authier FJ, Bassez G, Butori C, Chapon F, Delisle MB, Dubourg O, Feasson L, Gherardi R, Lacroix C, Laquerriere A, Letournel F, Magy L, Maisonobe T, Marcorelles P, Maurage CA, Mezin P, Mussini JM, Penisson-Besnier I, Romero NB, Streichenberger N, Vallat JM, Viennet G, Vital A, Voit T, Boucharef W, Figarella-Branger D (2010) Management of muscle and nerve biopsies: expert guidelines from two French professional societies, Société française de myologie et de l’Association française contre les myopathies. Rev Neurol (Paris) 166(5):477–485PubMedCrossRef

34.

Muscle Biopsy: a practical approach. V Dubrowitz, C Sewry, A Oldfors. Fourth edition, Saunders Ed 2013.

35.

Na SJ, Kim WJ, Kim SM et al (2013) Clinical, immunohistochemical, Western blot, and genetic analysis in dystrophinopathy. J Clin Neurosci 20:1099–1105PubMedCrossRef

36.

Ripolone M, Velardo D, Mondello S, Zanotti S, Magri F, Minuti E, Cazzaniga S, Fortunato F, Ciscato P, Tiberio F, Sciacco M, Moggio M, Bettica P, Comi GP (2022) Muscle histological changes in a large cohort of patients affected with Becker muscular dystrophy. Acta Neuropathol Commun 10(1):48PubMedPubMedCentralCrossRef

37.

Anthony K, Arechavala-Gomeza V, Taylor LE et al (2014) Dystrophin quantification: biological and translational research implications. Neurology 83:2062–2069PubMedPubMedCentralCrossRef

38.

Chevron MP, Tuffery S, Echenne B, Demaille J, Claustres M (1992) Becker muscular dystrophy: demonstration of the carrier status of a female by immunoblotting and immunostaining. Neuromuscul Disord 2(1):47–50PubMedCrossRef

39.

Haginoya K, Yamamoto K, Iinuma K, Yanagisawa T, Ichinohasama Y, Shimmoto M, Suzuki Y, Tada K (1991) Dystrophin immunohistochemistry in a symptomatic carrier of Becker muscular dystrophy. J Neurol 238(7):375–378PubMedCrossRef

40.

Pegoraro E, Schimke RN, Garcia C et al (1995) Genetic and biochemical normalization in female carriers of Duchenne muscular dystrophy: evidence for failure of dystrophin production in dystrophin-competent myonuclei. Neurology 45:677–690PubMedCrossRef

41.

Monaco AP, Bertelson CJ, Liechti-Gallati S, Moser H, Kunkel LM (1988) An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus. Genomics 2(1):90–95PubMedCrossRef

42.

Bello L, Campadello P, Barp A, Fanin M, Semplicini C, Sorarù G, Caumo L, Calore C, Angelini C, Pegoraro E (2016) Functional changes in Becker muscular dystrophy: implications for clinical trials in dystrophinopathies. Sci Rep 1(6):32439CrossRef

43.

Leturcq F, Tuffery-Giraud S (2015) Aspects génétiques et moléculaires des dystrophinopathies. Arch Pediatr 22(12 Suppl 1):12S3-12S11PubMedCrossRef

44.

Aartsma-Rus A, Ginjaar IB, Bushby K (2016) The importance of genetic diagnosis for Duchenne muscular dystrophy. J Med Genet 53(3):145–151PubMedCrossRef

45.

Muntoni F, Torelli S, Ferlini A (2003) Dystrophin and mutations: one gene, several proteins, multiple phenotypes. Lancet 44:731–740CrossRef

46.

Tuffery-Giraud S, Béroud C, Leturcq F et al (2009) Genotype-phenotype analysis in 2405 patients with a dystrophinopathy using the UMD-DMD database: a model of nationwide knowledgebase. Hum Mutat 30:934–945PubMedCrossRef

47.

Janssen B, Hartmann C, Scholz V et al (2005) MLPA analysis for the detection of deletions, duplications and complex réarrangements in the dystrophin gene: potential and pitfalls. Neurogenetics 6:29–35PubMedCrossRef

48.

Biancalana V, Laporte J (2015) Diagnostic use of massively parallel sequencing in neuromuscular diseases: towards an integrated diagnosis. J Neuromuscul Dis 2:87–92

49.

Tuffery-Giraud S, Saquet C, Thorel D et al (2005) Mutation Spectrum leading to an attenuated phenotype in dystrophinopathies. Eur J Hum Genet 13:1254–1260PubMedCrossRef

50.

Schwartz M, Hertz JM, Sveen ML et al (2005) LGMD2I presenting with a characteristic Duchenne or Becker muscular dystrophy phenotype. Neurology 64:1635–1637PubMedCrossRef

51.

Bushby KM, Collins J, Hicks D (2014) Collagen type VI myopathies. Adv Exp Med Biol 802:185–199PubMedCrossRef

52.

Domingos J, Sarkozy A, Scoto M, Muntoni F (2017) Dystrophinopathies and Limb-Girdle muscular dystrophies. Neuropediatrics 48(4):262–272PubMedCrossRef

53.

DeSimone AM, Pakula A, Lek A, Emerson CP Jr (2017) Facioscapulohumeral muscular dystrophy. Compr Physiol 7(4):1229–1279PubMedCrossRef

54.

Selva-O’Callaghan A, Pinal-Fernandez I, Trallero-Araguás E, Milisenda JC, Grau-Junyent JM, Mammen AL (2018) Classification and management of adult inflammatory myopathies. Lancet Neurol 17(9):816–828PubMedCrossRef

55.

Juntas Morales R, Pageot N, Taieb G, Camu W (2017) Adult-onset spinal muscular atrophy: an update. Rev Neurol (Paris) 173(5):308–319PubMedCrossRef

56.

Annonce et accompagnement du diagnostic d’un patient ayant une maladie chronique. French Health authority. https://www.has-sante.fr/upload/docs/application/pdf/2014-03/guide_annonce_diagnostic_format_court_web.pdf

57.

Angelini C, Marozzo R, Pegoraro V (2019) Current and emerging therapies in Becker muscular dystrophy (BMD). Acta Myol 38(3):172–179PubMedPubMedCentral

58.

Maggi L, Moscatelli M, Frangiamore R, Mazzi F, Verri M, De Luca A, Pasanisi MB, Baranello G, Tramacere I, Chiapparini L, Bruzzone MG, Mantegazza R, Aquino D (2020) Quantitative muscle MRI protocol as possible biomarker in becker muscular dystrophy. Clin Neuroradiol 31:257–266PubMedCrossRef

59.

McDonald CM, Henricson EK, Abresch RT et al (2013) The 6-minute walk test and other clinical endpoints in Duchenne muscular dystrophy: reliability, concurrent validity, and minimal clinically important differences from a multicenter study. Muscle Nerve 48:357–368PubMedPubMedCentralCrossRef

60.

Florence JM, Pandya S, King WM et al (1984) Clinical trials in Duchenne dystrophy. Standardization and reliability of evaluation procedures. Phys Ther 64(1):41–45PubMedCrossRef

61.

Brooke MH, Fenichel GM, Griggs RC, Mendell JR, Moxley R, Miller JP, Province MA (1983) Clinical investigation in Duchenne dystrophy: 2. Determination of the “power” of therapeutic trials based on the natural history. Muscle Nerve 6(2):91–103PubMedCrossRef

62.

Vignos PJ Jr, Spencer GE Jr, Archibald KC (1963) Management of progressive muscular dystrophy in childhood. JAMA 184:89–96PubMedCrossRef

63.

Vuillerot C, Rippert P, Roche S, Bérard C, Margirier F, de Lattre C, Poirot I, Berruyer A, Tiffreau V, Fournier-Mehouas M, Bouhour F, Urtizberea JA, Renders A, Ecochard R, Le groupe d’étude NM-Score (2013) Development and validation of a motor function classification in patients with neuromuscular disease: the NM-score. Ann Phys Rehabil Med 56(9–10):673–686PubMedCrossRef

64.

Vuillerot C, Meilleur KG, Jain M, Waite M, Wu T, Linton M, Datsgir J, Donkervoort S, Leach ME, Rutkowski A, Rippert P, Payan C, Iwaz J, Hamroun D, Bérard C, Poirot I, Bönnemann CG (2014) English cross-cultural translation and validation of the neuromuscular score: a system for motor function classification in patients with neuromuscular diseases. Arch Phys Med Rehabil 95(11):2064-2070.e1PubMedPubMedCentralCrossRef

65.

De Lattre C, Payan C, Vuillerot C, Rippert P, de Castro D, Bérard C, Poirot I (2013) Motor function measure: validation of a short form for young children with neuromuscular diseases. Arch Phys Med Rehabil 94(11):2218–2226PubMedCrossRef

66.

Emery N, Strachan K, Kulshrestha R, Kuiper JH, Willis T (2022) Evaluating the feasibility and reliability of remotely delivering and scoring the North Star ambulatory assessment in ambulant patients with duchenne muscular dystrophy. Children (Basel) 9(5):728PubMed

67.

James MK, Alfano LN, Muni-Lofra R, Reash NF, Sodhi J, Iammarino MA, Moat D, Shannon K, McCallum M, Richardson M, Eagle M, Straub V, Marini-Bettolo C, Lowes LP, Mayhew AG (2022) Validation of the North star assessment for limb-girdle type muscular dystrophies. Phys Ther 102(10):pzac113PubMedPubMedCentralCrossRef

68.

Boulay C, Finidori G (2015) Aspects fonctionnels et orthopédiques des dystrophinopathies [Functional and orthopaedic aspects of dystrophinopathies]. Arch Pediatr 22(12 Suppl 1):12S42-12S50PubMedCrossRef

69.

Lanza G, Pino M, Fisicaro F, Vagli C, Cantone M, Pennisi M, Bella R, Bellomo M (2020) Motor activity and Becker’s muscular dystrophy: lights and shadows. Phys Sportsmed 48(2):151–160PubMedCrossRef

70.

Alemdaroğlu I, Karaduman A, Yilmaz ÖT, Topaloğlu H (2015) Different types of upper extremity exercise training in Duchenne muscular dystrophy: effects on functional performance, strength, endurance, and ambulation. Muscle Nerve 51(5):697–705PubMedCrossRef

71.

Kroenke K, Spitzer RL, Williams JB (2001) The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 16(9):606–613PubMedPubMedCentralCrossRef

72.

Spitzer RL, Kroenke K, Williams JB, Löwe B (2006) A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med 166(10):1092–1097PubMedCrossRef

73.

Dany A, Rapin A, Lavrard B, Saoût V, Réveillère C, Bassez G, Tiffreau V, Péréon Y, Sacconi S, Eymard B, Dramé M, Jolly D, Novella JL, Hardouin JB, Boyer FC (2017) The quality of life in genetic neuromuscular disease questionnaire: Rasch validation of the French version. Muscle Nerve 56(6):1085–1091PubMedCrossRef

74.

Bushby K, Muntoni F, Bourke JP (2003) 107th ENMC international workshop: the management of cardiac involvement in muscular dystrophy and myotonic dystrophy. 7th–9th June 2002, Naarden, the Netherlands. Neuromuscul Disord 13:166–72

75.

Nigro G, Comi LI, Politano L et al (1995) Evaluation of the cardiomyopathy in Becker muscular dystrophy. Muscle Nerve 18:283–291PubMedCrossRef

76.

McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, Burri H, Butler J, Čelutkienė J, Chioncel O, Cleland JGF, Coats AJS, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Piepoli MF, Price S, Rosano GMC, Ruschitzka F, Skibelund AK, ESC Scientific Document Group (2022) 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. Rev Esp Cardiol (Engl Ed) 75(6):523 (English, Spanish)PubMed

77.

Quinlivan R, Ball J, Dunckley M, Thomas DJ, Flinter F, Morgan-Hughes J (1995) Becker muscular dystrophy presenting with complete heart block in the sixth decade. J Neurol 242(6):398–400PubMedCrossRef

78.

Nolan MA, Jones ODH, Pedersen RL et al (2003) Cardiac assessment in childhood carriers of Duchenne and Becker muscular dystrophies. Neuromuscul Disord 13:129–132PubMedCrossRef

79.

Politano L, Nigro V, Nigro G et al (1996) Development of cardiomyopathy in female carriers of Duchenne and Becker muscular dystrophies. JAMA 275:1335–1338PubMedCrossRef

80.

Rahbek J, Steffensen BF, Bushby K et al (2015) 206th ENMC International Workshop: care for a novel group of patients—adults with Duchenne muscular dystrophy Naarden, The Netherlands, 23–25 May 2014. Neuromuscul Disord 25:727–738PubMedCrossRef

81.

Stalens C, Motté L, Béhin A, Ben Yaou R, Leturcq F, Bassez G, Laforêt P, Fontaine B, Ederhy S, Masingue M, Saadi M, Louis SL, Berber N, Stojkovic T, Duboc D, Wahbi K (2021) Improved cardiac outcomes by early treatment with angiotensin-converting enzyme inhibitors in becker muscular dystrophy. J Neuromuscul Dis 8(4):495–502PubMedPubMedCentralCrossRef

82.

Viollet L, Thrush PT, Flanigan KM et al (2012) Effects of angiotensin-converting enzyme inhibitors and/or beta blockers on the cardiomyopathy in Duchenne muscular dystrophy. Am J Cardio 110:98–102CrossRef

83.

American Academy of Pediatrics Section on Cardiology and Cardiac Surgery (2005) Cardiovascular health supervision for individuals affected by Duchenne or Becker muscular dystrophy. Pediatrics 116:1569–1573CrossRef

84.

Lo Mauro A, Aliverti A (2016) Physiology of respiratory disturbances in muscular dystrophies. Breathe 12:318–327PubMedPubMedCentralCrossRef

85.

Yuko Nakamura et col. Brain & Development (2018) Identification of sleep hypoventilation in young individuals with Becker muscular dystrophy: a pilot study

86.

Finder JD (2009) A 2009 perspective on the 2004 American Thoracic Society statement, “respiratory care of the patient with Duchenne muscular dystrophy.” Pediatrics 123:S239–S241PubMedCrossRef

87.

Michelle C, Hui-Leng T, Andrew B, Mark R, Anita KS (2015) Long term non-invasive ventilation in children: impact on survival and transition to adult care. PLoS One 10(5):e0125839

88.

Annane D, Orlikowski D, Chevret S (2014) Cochrane Database of Systematic Reviews 2014, Issue 12. Nocturnal mechanical ventilation for chronic hypoventilation in patients with neuromuscular and chest wall disorders (Review)

89.

Hansen-Flaschen J, Ackrivo J (2023) Practical guide to management of long-term noninvasive ventilation for adults with chronic neuromuscular disease. Respir Care. https://doi.org/10.4187/respcare.10349CrossRefPubMed

90.

Elverson J, Evans H, Dewhurst F (2023) Palliation, end of life care and ventilation withdrawal in neuromuscular disorders. Chron Respir Dis 20:14799731231175912PubMedPubMedCentralCrossRef

91.

Yamada Y, Kawakami M, Wada A, Otsuka T, Muraoka K, Liu M (2018) A comparison of swallowing dysfunction in Becker muscular dystrophy and Duchenne muscular dystrophy. Disabil Rehabil 40(12):1421–1425PubMedCrossRef

92.

Okan M, Alper E, Cil E, Eralp O, Ağir H (1997) Gastric emptying time in children with progressive muscular dystrophy. Turk J Pediatr 39(1):69–74PubMed

93.

Morse CI, Higham K, Bostock EL, Jacques MF (2020) Urinary incontinence in men with Duchenne and Becker muscular dystrophy. PLoS One 15(5):e0233527PubMedPubMedCentralCrossRef

94.

Bertrand LA, Askeland EJ, Mathews KD, Erickson BA, Cooper CS (2016) Prevalence and bother of patient-reported lower urinary tract symptoms in the muscular dystrophies. J Pediatr Urol 12(6):398.e1-398.e4PubMedCrossRef

95.

Mahoney FI, Barthel DW (1965) Functional evaluation: the Barthel index. Md State Med J 14:61–65PubMed

96.

Avery K, Donovan J, Peters TJ, Shaw C, Gotoh M, Abrams P (2004) ICIQ: a brief and robust measure for evaluating the symptoms and impact of urinary incontinence. Neurourol Urodyn Off J Int Cont Soc 23(4):322–330CrossRef

97.

Houwen-van Opstal SLS, Rodwell L, Bot D, Daalmeyer A, Willemsen MAAP, Niks EH, de Groot IJM (2022) BMI-z scores of boys with Duchenne muscular dystrophy already begin to increase before losing ambulation: a longitudinal exploration of BMI, corticosteroids and caloric intake. Neuromuscul Disord 32(3):236–244PubMedCrossRef

98.

Coubes C (2015) Conseil génétique dans les dystrophinopathies. Arch Pediatr 22(12 Suppl 1):12S12-12S17PubMedCrossRef

99.

Segura LG, Lorenz JD, Weingarten TN, Scavonetto F, Bojaniƒá K, Selcen D, Sprung J (2013) Anesthesia and Duchenne or Becker muscular dystrophy: review of 117 anesthetic exposures. Paediatr Anaesth 23(9):855–864PubMedCrossRef

100.

Bush A, Dubowitz V (1991) Fatal rhabdomyolysis complicating general anaesthesia in a child with Becker muscular dystrophy. Neuromuscul Disord 1:201–204PubMedCrossRef

101.

Cripe LH, Tobias JD (2013) Cardiac considerations in the operative management of the patient with Duchenne or Becker muscular dystrophy. Paediatr Anaesth 23(9):777–784PubMedCrossRef

102.

van den Bersselaar LR, Heytens L, Silva HCA, Reimann J, Tasca G, Díaz-Cambronero Ó, Løkken N, Hellblom A, Hopkins PM, Rueffert H, Bastian B, Vilchez JJ, Gillies R, Johannsen S, Veyckemans F, Muenster T, Klein A, Litman R, Jungbluth H, Riazi S, Voermans NC, Snoeck MMJ (2022) European Neuromuscular Centre consensus statement on anaesthesia in patients with neuromuscular disorders. Eur J Neurol 29(12):3486–3507PubMedPubMedCentralCrossRef

103.

Esposito S, Bruno C, Berardinelli A, Filosto M, Mongini T, Morandi L, Musumeci O, Pegoraro E, Siciliano G, Tonin P, Marrosu G, Minetti C, Servida M, Fiorillo C, Conforti G, Scapolan S, Ansaldi F, Vianello A, Castaldi S, Principi N, Toscano A, Moggio M (2014) Vaccination recommendations for patients with neuromuscular disease. Vaccine 32(45):5893–5900PubMedCrossRef

104.

Dowell D, Ragan KR, Jones CM, Baldwin GT, Chou R (2022) CDC clinical practice guideline for prescribing opioids for pain—United States, 2022. MMWR Recomm Rep 71(3):1–95PubMedPubMedCentralCrossRef

105.

Les cartes d’urgences Maladies rares. Filière FILNEMUS. https://www.filnemus.fr/laccompagnement/les-urgences/les-cartes-durgence-filnemus

106.

Zagorda B, Camdessanché JP, Féasson L (2021) Pregnancy and myopathies: reciprocal impacts between pregnancy, delivery, and myopathies and their treatments. A clinical review. Rev Neurol (Paris) 177(3):225–234PubMedCrossRef

Titel: Diagnosis and management of Becker muscular dystrophy: the French guidelines
verfasst von: Armelle Magot
Karim Wahbi
France Leturcq
Sandrine Jaffre
Yann Péréon
Guilhem Sole
The French BMD working group
Publikationsdatum: 09.07.2023
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Neurology / Ausgabe 10/2023
Print ISSN: 0340-5354
Elektronische ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-023-11837-5

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Nicht Creutzfeldt Jakob, sondern Abführtee-Vergiftung

29.05.2024 Hyponatriämie Nachrichten

Eine ältere Frau trinkt regelmäßig Sennesblättertee gegen ihre Verstopfung. Der scheint plötzlich gut zu wirken. Auf Durchfall und Erbrechen folgt allerdings eine Hyponatriämie. Nach deren Korrektur kommt es plötzlich zu progredienten Kognitions- und Verhaltensstörungen.

Schutz der Synapsen bei Alzheimer

29.05.2024 Morbus Alzheimer Nachrichten

Mit einem Neurotrophin-Rezeptor-Modulator lässt sich möglicherweise eine bestehende Alzheimerdemenz etwas abschwächen: Erste Phase-2-Daten deuten auf einen verbesserten Synapsenschutz.

Sozialer Aufstieg verringert Demenzgefahr

24.05.2024 Demenz Nachrichten

Ein hohes soziales Niveau ist mit die beste Versicherung gegen eine Demenz. Noch geringer ist das Demenzrisiko für Menschen, die sozial aufsteigen: Sie gewinnen fast zwei demenzfreie Lebensjahre. Umgekehrt steigt die Demenzgefahr beim sozialen Abstieg.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2023

Frequency of demyelinating disease activity following immune checkpoint inhibitor cancer immunotherapy

Satralizumab as a treatment for pediatric-onset neuromyelitis optica spectrum disorder with cluster attack: a case report

Functional connectivity modifications in monoaminergic circuits occur in fatigued MS patients treated with fampridine and amantadine

Correction to: Physical fitness moderates the association between brain network impairment and both motor function and cognition in progressive multiple sclerosis

Characterizing long-COVID brain fog: a retrospective cohort study

A new genetic cause of spastic ataxia: the p.Glu415Lys variant in TUBA4A